Vanda Pharmaceuticals Price to Free Cash Flow Ratio 2006-2021 | VNDA

Historical price to free cash flow ratio values for Vanda Pharmaceuticals (VNDA) since 2006. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Vanda Pharmaceuticals Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2022-01-19 13.90 14.12
2021-09-30 17.14 $0.98 17.41
2021-06-30 21.51 $0.99 21.84
2021-03-31 15.02 $1.09 13.79
2020-12-31 13.14 $0.91 14.51
2020-09-30 9.66 $0.75 12.93
2020-06-30 11.44 $0.69 16.64
2020-03-31 10.36 $0.62 16.69
2019-12-31 16.41 $0.82 20.03
2019-09-30 13.28 $0.94 14.11
2019-06-30 14.09 $0.99 14.22
2019-03-31 18.40 $0.70 26.19
2018-12-31 26.13 $0.56 46.79
2018-09-30 22.95 $0.34 68.41
2018-06-30 19.05 $0.22 86.04
2018-03-31 16.85 $0.08 207.77
2017-12-31 15.20 $-0.08 0.00
2017-09-30 17.90 $-0.20 0.00
2017-06-30 16.30 $-0.22 0.00
2017-03-31 14.00 $-0.24 0.00
2016-12-31 15.95 $-0.22 0.00
2016-09-30 16.64 $-0.20 0.00
2016-06-30 11.19 $-0.35 0.00
2016-03-31 8.36 $0.01 0.00
2015-12-31 9.31 $0.23 39.65
2015-09-30 11.28 $0.04 286.29
2015-06-30 12.69 $-0.05 0.00
2015-03-31 9.30 $-1.42 0.00
2014-12-31 14.32 $-2.24 0.00
2014-09-30 10.38 $-2.34 0.00
2014-06-30 16.18 $-2.39 0.00
2014-03-31 16.25 $-1.59 0.00
2013-12-31 12.41 $-1.19 0.00
2013-09-30 10.95 $-1.37 0.00
2013-06-30 8.08 $-1.46 0.00
2013-03-31 3.92 $-1.61 0.00
2012-12-31 3.70 $-1.66 0.00
2012-09-30 4.03 $-1.61 0.00
2012-06-30 4.40 $-1.51 0.00
2012-03-31 4.79 $-1.28 0.00
2011-12-31 4.76 $-1.02 0.00
2011-09-30 4.95 $-0.76 0.00
2011-06-30 7.14 $-0.68 0.00
2011-03-31 7.29 $-0.32 0.00
2010-12-31 9.46 $-0.38 0.00
2010-09-30 6.68 $6.80 0.98
2010-06-30 6.61 $6.66 0.99
2010-03-31 11.54 $6.24 1.85
2009-12-31 11.25 $6.27 1.79
2009-09-30 11.64 $-0.94 0.00
2009-06-30 11.77 $-1.14 0.00
2009-03-31 0.90 $-1.29 0.00
2008-12-31 0.50 $-1.76 0.00
2008-09-30 0.94 $-2.20 0.00
2008-06-30 3.29 $-2.08 0.00
2008-03-31 3.87 $-2.04 0.00
2007-12-31 6.88 $-1.96 0.00
2007-09-30 13.91 $-2.73 0.00
2007-06-30 20.26 $-2.95 0.00
2007-03-31 24.36 $-3.84 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.790B $0.248B
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.033B 9.10
Bio-Rad Laboratories (BIO.B) United States $17.971B 36.47
QIAGEN (QGEN) Netherlands $11.044B 18.70
Biohaven Pharmaceutical Holding (BHVN) United States $7.729B 0.00
Emergent Biosolutions (EBS) United States $2.541B 9.14
Arcus Biosciences (RCUS) United States $2.414B 0.00
Myovant Sciences (MYOV) United Kingdom $1.374B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.167B 0.00
Zymeworks (ZYME) Canada $0.623B 0.00
Ambrx Biopharma (AMAM) United States $0.231B 0.00
SQZ Biotechnologies (SQZ) United States $0.214B 0.00
Enzo Biochem (ENZ) United States $0.161B 20.75